Skip to content

Study · Not a test of the peptide alone · 2018

9 results

Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Tzanetakos C, Bargiota A, Kourlaba G, Gourzoulidis G, Maniadakis N

Clinical drug investigation1 Jan 2018Cited by 10 (Europe PMC)

PMID29080210 (opens in a new tab)DOI10.1007/s40261-017-0586-0 (opens in a new tab)PepBankPUB-29080210
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a lifetime model for Greek adults with type 2 diabetes, exenatide added 0.458 QALYs versus insulin glargine.

    In plain wordsIn a computer model, exenatide increased quality-adjusted life-years versus insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIncremental quality-adjusted life-years versus insulin glargine
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of €2061 or €110, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a lifetime model for Greek adults with type 2 diabetes, exenatide added 0.039 QALYs versus liraglutide.

    In plain wordsIn a computer model, exenatide increased quality-adjusted life-years versus liraglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIncremental quality-adjusted life-years versus liraglutide
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Liraglutide 1.2 mg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of €2061 or €110, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the Greek lifetime model, exenatide increased costs by €2061 versus insulin glargine.

    In plain wordsIn a computer model for Greece, exenatide cost more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdditional costs versus insulin glargine
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of €2061 or €110, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the Greek lifetime model, exenatide increased costs by €110 versus liraglutide.

    In plain wordsIn a computer model for Greece, exenatide cost more than liraglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdditional costs versus liraglutide
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Liraglutide 1.2 mg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of €2061 or €110, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the Greek model, exenatide had an incremental cost-effectiveness ratio of €4499/QALY versus insulin glargine.

    In plain wordsIn a computer model, exenatide cost €4499 per additional quality-adjusted life-year versus insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIncremental cost-effectiveness ratio versus insulin glargine
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The ICER for ExQW was €4499/QALY compared with IG and €2827/QALY compared with Lira1.2mg.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 06Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the Greek model, exenatide had an incremental cost-effectiveness ratio of €2827/QALY versus liraglutide.

    In plain wordsIn a computer model, exenatide cost €2827 per additional quality-adjusted life-year versus liraglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIncremental cost-effectiveness ratio versus liraglutide
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Liraglutide 1.2 mg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The ICER for ExQW was €4499/QALY compared with IG and €2827/QALY compared with Lira1.2mg.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 07Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In the Greek exenatide model, results were robust across one-way and scenario analyses.

    In plain wordsIn a computer model, exenatide results remained robust across sensitivity analyses.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableCost-effectiveness sensitivity analyses
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Results were robust across various one-way and scenario analyses.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 08Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    At €36,000/QALY, the Greek model estimated a 100% probability that exenatide was cost effective versus insulin glargine.

    In plain wordsIn a computer model, exenatide had a 100% probability of cost effectiveness versus insulin glargine at the stated threshold.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableProbability of cost effectiveness versus insulin glargine
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    At the defined willingness-to-pay threshold of €36,000/QALY, probabilistic sensitivity analysis showed that ExQW had a 100 or 88.2% probability of being cost effective relative to IG or Lira1.2mg, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  9. 09Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    At €36,000/QALY, the Greek model estimated an 88.2% probability that exenatide was cost effective versus liraglutide.

    In plain wordsIn a computer model, exenatide had an 88.2% probability of cost effectiveness versus liraglutide at the stated threshold.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableProbability of cost effectiveness versus liraglutide
    Study

    n: not reported in source

    Cardiff Diabetes Model
    Comparator
    Liraglutide 1.2 mg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    At the defined willingness-to-pay threshold of €36,000/QALY, probabilistic sensitivity analysis showed that ExQW had a 100 or 88.2% probability of being cost effective relative to IG or Lira1.2mg, respectively.
    1 context sentence
    Summary · context
    The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.